Last reviewed · How we verify
AZD6738 and olaparib
PARP inhibitor
PARP inhibitor Used for Ovarian cancer, Breast cancer.
At a glance
| Generic name | AZD6738 and olaparib |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | PARP inhibitor |
| Target | PARP |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
AZD6738 and olaparib are PARP inhibitors that work by blocking the action of poly (ADP-ribose) polymerase (PARP), an enzyme involved in DNA repair. By inhibiting PARP, these drugs can induce DNA damage and trigger cell death in cancer cells.
Approved indications
- Ovarian cancer
- Breast cancer
Common side effects
- Nausea
- Vomiting
- Fatigue
Key clinical trials
- Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial) (PHASE2)
- Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer (PHASE2)
- Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer (PHASE2)
- AMTEC IIT: Phase 2 Multiarm Study in TNBC (PHASE2)
- Olaparib With Ceralasertib in Recurrent Osteosarcoma (PHASE2)
- ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss (PHASE2)
- Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (PHASE2)
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD6738 and olaparib CI brief — competitive landscape report
- AZD6738 and olaparib updates RSS · CI watch RSS
- AstraZeneca portfolio CI